Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 13CNS 7Other hematologic neoplasm 4Sarcoma 3Plasma cell 2Myeloid 1Dermatologic 1

Conditions

Gliosarcoma 3Glioblastoma 3Glioma 2

Interventions

Radiotherapy 221Cyclophosphamide 211Doxorubicin 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 81Irinotecan 79pembrolizumab 75Radiation 70Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Surgical Procedures, Operative 57Peripheral Blood Stem Cell Transplantation 57Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
carmustine, poliferprosan 20 drug combination × Sarcoma × Clear all
NCT00669669 2022-05-18

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
12 enrolled 13 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT01186406 2019-02-15

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Duke University

Phase 2 Terminated
41 enrolled 9 charts
CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

NCT00735436 2013-02-11

A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)

Duke University

Phase 2 Terminated
18 enrolled 11 charts
CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡